Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female~* 1 month to 16 years of age at enrollment~* neurological impairment defined as subnormal (-2 S.D.) motor and/or cognitive ability from a variety of etiologies~* chronic irritability defined as symptoms suggesting pain to the child's caregiver recurrently over a 4-week of greater time period~* Subject must have an acceptable surrogate capable of giving consent on the subject's behalf~Exclusion Criteria:~* Children with resolved symptoms after treatment of identified sources of pain~* Identified potential source of irritability without adequate trial of appropriate management~* Ketogenic diet~* Renal insufficiency or failure~* Current treatment with gabapentin or pregabalin for another existing condition.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin, then placebo (Type: EXPERIMENTAL): Participants first receive gabapentin 3 times per day, with varying dosing based on the protocol. After 34-38 days, a washout period of 3 days occurs, before then receiving the placebo dose for 32 days.
- Placebo, then Gabapentin (Type: EXPERIMENTAL): Participants first receive placebo 3 times per day. After 34-38 days, a washout period of 3 days occurs, before then receiving Gabapentin, with varying dosing based on the protocol, for 32 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).